Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lifecore Biomedical, Inc. \De\ (LFCR) Retained Earnings (2016 - 2025)

Lifecore Biomedical, Inc. \De\ has reported Retained Earnings over the past 15 years, most recently at -$205.2 million for Q2 2025.

  • For Q2 2025, Retained Earnings fell 23.25% year-over-year to -$205.2 million; the TTM value through May 2025 reached -$205.2 million, down 23.25%, while the annual FY2025 figure was -$205.2 million, 23.25% down from the prior year.
  • Retained Earnings for Q2 2025 was -$205.2 million at Lifecore Biomedical, Inc. \De\, down from -$204.1 million in the prior quarter.
  • Over five years, Retained Earnings peaked at $39.0 million in Q1 2021 and troughed at -$205.2 million in Q2 2025.
  • A 5-year average of -$101.7 million and a median of -$149.3 million in 2023 define the central range for Retained Earnings.
  • Biggest five-year swings in Retained Earnings: surged 4790.5% in 2021 and later crashed 66085.31% in 2023.
  • Year by year, Retained Earnings stood at -$816000.0 in 2021, then tumbled by 12491.3% to -$102.7 million in 2022, then tumbled by 70.39% to -$175.1 million in 2023, then dropped by 9.36% to -$191.5 million in 2024, then decreased by 7.2% to -$205.2 million in 2025.
  • Business Quant data shows Retained Earnings for LFCR at -$205.2 million in Q2 2025, -$204.1 million in Q1 2025, and -$191.5 million in Q4 2024.